Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans

Drug Metabolism and Disposition

Volumn 24, Issue 1, 1996, Pages 91-95

  Barbhaiya, Rashmi H ^a   Dandekar, Kishor A ^a,b   Greene, Douglas S ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Bertex Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; CARBON 14; DRUG METABOLITE; NEFAZODONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG METABOLISM; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; INFUSIONS, INTRAVENOUS; MALE; REFERENCE VALUES; TRIAZOLES;

EID: 0030048621     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. J. P. Feighner, R. Pambakian, R. C. Fowler, W. F. Boyer, and M. F. D'Amico: A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression, Psychopharmacol. Bull. 25, 219-221 (1989).
2. A. S. Eison, M. S. Eison, J. R. Torrente, R. N. Wright, and R. D. Yucca: Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol. Bull. 26, 311-315 (1990).
3. D. P. Taylor, D. W. Smith, D. K. Hyslop, L. A. Riblet, and D. L. Temple, Jr.: Receptor binding and atypical antidepressant drug discovery. In "Receptor Binding in Drug Research" (R. A. O'Brien, ed.), pp. 151-165. Marcel Dekker, New York, 1986.
4. D. K. Hyslop, L. E. Allen, and D. P. Taylor: Triazolo antidepressants do not inhibit monoamine oxidase. Drug Dev. Res. 12, 77-79 (1988).
5. S. Kaul, U. A. Shukla, and R. H. Barbhaiya: Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. J. Clin. Pharmacol. 35, 830-839 (1995).
6. 14]nefazodone in the dog. Drug Metab. Dispos. 21, 502-507 (1993).
7. J. van Harten: Clinical pharmacokinetics of selective seratonin reuptake inhibitors. Clin. Pharmacokinet. 24, 203-220 (1993).
8. I. F. Tulloch and A. M. Johnson: The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J. Clin. Psychiatry 53 (Suppl.), 7-12 (1992).
9. B. E. Leonard: The comparative pharmacology of new antidepressants. J. Clin. Psychiatry 54 (Suppl.), 3-15 (1993).
10. D. A. Ciraulo and R. I. Shader: Fluoxetine drug-drug interactions. I. Antidepressants and antipsychotics. J. Clin. Psychopharmacol. 10, 48-50 (1990).